The wearable neurotechnology market is gaining attention as startups like Neurovalens explore non-invasive brain-stimulation therapeutics. This sector, which has raised significantly less funding than invasive technologies, is seen as a cost-effective alternative for treating various conditions, including anxiety, insomnia, and obesity. With projections estimating the market could grow from $14 billion to $40 billion by 2030, investors are increasingly optimistic. Neurovalens, having secured FDA approvals for two devices, plans further clinical trials and product launches, highlighting the potential for wearable neurotech to revolutionize mental health treatments.